文献速递妇科生殖医学

子宫输卵管泡沫超声造影是评估输卵管通畅性的新金标准吗?系统综述与荟萃分析

Is hysterosalpingo-foam sonography the new gold standard for assessing tubal patency? A systematic review and meta-analysis.
PubMed 文献 · Reprod Biomed Online · 2024-07-18

本研究通过系统综述与荟萃分析比较子宫输卵管泡沫超声造影(HyFosy)与其他输卵管通畅性检查的有效性、安全性和耐受性,共纳入2012年至2023年1月发表的20项研究。结果显示,94%的患者HyFosy与腹腔镜检查结果一致;HyFosy与子宫输卵管造影(HSG)在输卵管通畅性识别(总风险比0.98,95%CI 0.88-1.10)和操作失败(总风险比0.47,95%CI 0.07-3.05)方面无差异;视觉模拟评分疼痛评分支持HyFosy(总风险比1.09,95%CI 1.00-1.17),95%的患者评分<6;仅1%的患者在HyFosy后出现操作失败或副作用。作者认为HyFosy至少与HSG同样有效,应作为评估输卵管通畅性的一线工具全面整合,并认为制定纳入HyFosy的新指南和标准化该新操作至关重要。

要点

  • 94%的患者HyFosy与腹腔镜检查结果一致。
  • HyFosy与HSG在输卵管通畅性识别和操作失败方面无差异。
  • 视觉模拟评分疼痛评分支持HyFosy,95%的患者评分<6。

核心结论

  • HyFosy至少与HSG同样有效。
  • HyFosy应作为评估输卵管通畅性的一线工具全面整合。
  • 制定纳入HyFosy的新指南和标准化该新操作至关重要。

研究设计与样本

  • 遵循Cochrane协作网和PRISMA指南进行的系统综述与荟萃分析,检索PubMed和Cochrane Library,检索词为「HyFosy」。
  • 共纳入20项研究,发表于2012年至2023年1月。

主要发现

  • 94%的患者HyFosy与腹腔镜检查结果一致。
  • HyFosy与HSG在输卵管通畅性识别方面无差异(总风险比0.98,95%CI 0.88-1.10)。
  • HyFosy与HSG在操作失败方面无差异(总风险比0.47,95%CI 0.07-3.05)。
  • 视觉模拟评分疼痛评分支持HyFosy(总风险比1.09,95%CI 1.00-1.17);95%的患者评分<6。
  • 仅1%的患者在接受HyFosy后出现操作失败或副作用。

临床怎么用

  • 作者认为HyFosy应作为评估输卵管通畅性的一线工具全面整合。
  • 作者认为制定纳入HyFosy的新指南和标准化该新操作至关重要。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The aim of this study was to compare hysterosalpingo-foam sonography (HyFosy) with other tubal patency tests to analyse its efficacy, safety and tolerance. A systematic review and meta-analysis were performed following the Cochrane Collaboration and PRISMA guidelines by searching PubMed and the Cochrane Library using the term 'HyFosy'. In total, 20 studies, published from 2012 to January 2023, were included in this review. Information about the identification of tubal patency, agreement with laparoscopy, pain intensity, procedure failure, occurrence of pregnancy, side effects and treatment modalities was extracted. In 94% of patients, HyFosy had the same result as laparoscopy. No difference was found between HyFosy and hysterosalpingography (HSG) in terms of identification of tubal patency [total risk ratio (TRR) 0.98, 95% CI 0.88-1.10] and procedure failure (TRR 0.47, 95% CI 0.07-3.05). The visual analogue scale pain score was in favour of HyFosy (TRR 1.09, 95% CI 1.00-1.17); 95% of patients scored <6. Only 1% of patients had procedure failure or side effects after undergoing HyFosy. HyFosy is at least as efficient as HSG. HyFosy should be fully integrated as a first-line tool for the assessment of tubal patency. New guidelines for the inclusion of HyFosy in the assessment of tubal patency and standardization of this new procedure are essential.

来源:Reprod Biomed Online,查看原文。版权归原作者所有。

引用

  1. Gerard Cassiman E, Harter S, Mougel R, et al. Is hysterosalpingo-foam sonography the new gold standard for assessing tubal patency? A systematic review and meta-analysis. Reprod Biomed Online. 2024. PMID: 39522344. doi:10.1016/j.rbmo.2024.104380

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。